Anavex Life Sciences Corp. (NASDAQ:AVXL) Q3 2023 Earnings Conference Call August 8, 2023 8:30 AM ET
Company Participants
Clint Tomlinson - IR
Christopher Missling - President and CEO
Sandra Boenisch - Principal Financial Officer
Conference Call Participants
Soumit Roy - Jones Trading
Operator
Good morning and welcome to the Anavex Life Sciences’ Fiscal 2023 Third Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today’s call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. [Operator Instructions] Please note that this conference is being recorded. The call will also be available for replay on Anavex’s website at www.anavex.com.
With us today is Dr. Christopher Missling, President and Chief Executive Officer; and Sandra Boenisch, Principal Financial Officer.
Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. We encourage you to review the company’s filings with the SEC. This includes, without limitation, the company’s Forms 10-K and 10-Q which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements.
These factors may include, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights.
And with that, I’d like to turn the call over to Dr. Missling.
Christopher Missling
Thank you Clint and good morning everyone. Thank you for being with us today to review our most recently reported financial results and to provide our quarterly business update. We are very excited to be entering an important phase of the company with several key data readouts within the remainder of 2023 for blarcamesine.
First on Rett syndrome, in June we announced the completion of the placebo-controlled EXCELLENCE Phase 2/3 clinical trial RS-003 in pediatric patients with Rett syndrome and we're looking forward to the top-line data of this potentially pivotal clinical trial in the second half of 2023.
On June 12, we announced the publication of a new peer-reviewed study in the American Journal on Intellectual and Developmental Disabilities with relevance to this clinical trial entitled, Rett Syndrome Behaviour Questionnaire in Children and Adults with Rett Syndrome: Psychometric characterization and revised factor structure.